Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2026)

Aquestive Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$14.9 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 36.87% year-over-year to -$14.9 million in Q1 2026; TTM through Mar 2026 was -$43.8 million, a 10.67% increase from a year earlier, with the FY2025 full-year figure at -$52.5 million, down 46.12% from the prior year.
• Free Cash Flow declined to -$14.9 million in Q1 2026 per AQST's latest filing, from -$8.0 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $8.8 million in Q1 2023 and bottomed at -$23.5 million in Q1 2025.
• The 5-year median for Free Cash Flow is -$7.9 million (2025), against an average of -$7.1 million.
• Across the five-year window, Free Cash Flow surged 197.63% in 2022 and plunged 375.58% in 2024, its largest moves.
• Year by year, Free Cash Flow stood at $8.4 million in 2022, then slumped by 147.23% to -$4.0 million in 2023, then plunged by 67.75% to -$6.6 million in 2024, then slipped by 21.0% to -$8.0 million in 2025, then sank by 84.71% to -$14.9 million in 2026.
• Per Business Quant, the three latest AQST Free Cash Flow figures stand at -$14.9 million (Q1 2026), -$8.0 million (Q4 2025), and -$13.0 million (Q3 2025).